Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas

PET Clinics

Volumn 10, Issue 3, 2015, Pages 375-393

  Sheikhbahaei, Sara ^a   Marcus, Charles ^a   Hafezi Nejad, Nima ^a   Taghipour, Mehdi ^a   Subramaniam, Rathan M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Computed tomography; Fluorodeoxyglucose; Patient management; PET; Skeletal sarcoma; Soft tissue sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHONDROSARCOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; EWING SARCOMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MONITORING; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MALE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SARCOMA; SCINTISCANNING; SOFT TISSUE NEOPLASMS;

BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84931955662     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2015.03.003     Document Type: Review

References (145)

1. B. Kasper, P. Hohenberger, and L.G. Strauss The use of fluorine-18 fluorodeoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas Hell J Nucl Med 13 2010 40 44
2. J.N. Tewfik, and G.S. Greene Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay Curr Probl Diagn Radiol 37 2008 178 188
3. Available at: http://www.cancer.gov. Accessed April 2015.
4. Y.Y. Choi, J.Y. Kim, and S.O. Yang PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions Semin Musculoskelet Radiol 18 2014 133 148
5. E. Quak, A.C. van de Luijtgaarden, and L.F. de Geus-Oei Clinical applications of positron emission tomography in sarcoma management Expert Rev Anticancer Ther 11 2011 195 204
6. V. Paidpally, A. Chirindel, and S. Lam FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma Imaging Med 4 2012 633 647
7. D. Hadiprodjo, T. Ryan, and M.T. Truong Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters AJR Am J Roentgenol 198 2012 W185 W190
8. A. Agarwal, A. Chirindel, and B.A. Shah Evolving role of FDG PET/CT in multiple myeloma imaging and management AJR Am J Roentgenol 200 2013 884 890
9. T. Jackson, M.K. Chung, and G. Mercier FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site Nucl Med Commun 33 2012 305 312
10. J.M. Davison, R.M. Subramaniam, and D.S. Surasi FDG PET/CT in patients with HIV AJR Am J Roentgenol 197 2011 284 294
11. A.K. Tahari, K.C. Alluri, and H. Quon FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors Clin Nucl Med 39 2014 225 231
12. B. Shah, N. Srivastava, and A.E. Hirsch Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods Ann Nucl Med 26 2012 707 714
13. V. Paidpally, A.K. Tahari, and S. Lam Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years J Nucl Med 54 2013 2039 2045
14. C. Marcus, A. Ciarallo, and A.K. Tahari Head and neck PET/CT: therapy response interpretation criteria (Hopkins criteria)-interreader reliability, accuracy, and survival outcomes J Nucl Med 55 2014 1411 1416
15. A.J. Antoniou, C. Marcus, and A.K. Tahari Follow-up or surveillance 18F-FDG PET/CT and survival outcome in lung cancer patients J Nucl Med 55 2014 1062 1068
16. P. Sridhar, G. Mercier, and J. Tan FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors AJR Am J Roentgenol 202 2014 1114 1119
17. C. Marcus, V. Paidpally, and A. Antoniou 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management J Nucl Med 56 2015 204 208
18. D. Karantanis, D. Kalkanis, and J. Czernin Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians J Nucl Med 55 2014 1925 1929
19. C.M. Costelloe, H.H. Chuang, and J.E. Madewell FDG PET/CT of primary bone tumors AJR Am J Roentgenol 202 2014 W521 W531
20. S.M. Schuetze Utility of positron emission tomography in sarcomas Curr Opin Oncol 18 2006 369 373
21. M.R. Benz, N. Tchekmedyian, and F.C. Eilber Utilization of positron emission tomography in the management of patients with sarcoma Curr Opin Oncol 21 2009 345 351
22. H.W. Garner, M.J. Kransdorf, and J.J. Peterson Posttherapy imaging of musculoskeletal neoplasms Radiol Clin North Am 49 2011 1307 1323 vii
23. T. Volker, T. Denecke, and I. Steffen Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial J Clin Oncol 25 2007 5435 5441
24. E. Bastiaannet, H. Groen, and P.L. Jager The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis Cancer Treat Rev 30 2004 83 101
25. A.L. Folpe, R.H. Lyles, and J.T. Sprouse (F-18) Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clin Cancer Res 6 2000 1279 1287
26. J.J. Peterson F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors Semin Musculoskelet Radiol 11 2007 246 260
27. V. Evilevitch, W.A. Weber, and W.D. Tap Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas Clin Cancer Res 14 2008 715 720
28. C.C. Jaffe Response assessment in clinical trials: implications for sarcoma clinical trial design Oncologist 13 2008 14 18
29. A.D. Van den Abbeele The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 2008 8 13
30. R. Grimer, N. Athanasou, and C. Gerrand UK guidelines for the management of bone sarcomas Sarcoma 2010 2010 317462
31. R. Rakheja, W. Makis, and R. Tulbah Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas AJR Am J Roentgenol 201 2013 170 177
32. J.F. Eary, E.U. Conrad, and J. O'Sullivan Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome J Bone Joint Surg Am 96 2014 152 158
33. E.S. Choi, S.G. Ha, and H.S. Kim Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma Eur J Nucl Med Mol Imaging 40 2013 1836 1842
34. S.P. Hong, S.E. Lee, and Y.L. Choi Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters Skeletal Radiol 43 2014 641 648
35. S.M. Schuetze, B.P. Rubin, and C. Vernon Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy Cancer 103 2005 339 348
36. M.G. Fox, and B.M. Trotta Osteosarcoma: review of the various types with emphasis on recent advancements in imaging Semin Musculoskelet Radiol 17 2013 123 136
37. W. Brenner, K.H. Bohuslavizki, and J.F. Eary PET imaging of osteosarcoma J Nucl Med 44 2003 930 942
38. C.B. Kong, B.H. Byun, and I. Lim (1)(8)F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma Eur J Nucl Med Mol Imaging 40 2013 728 736
39. L. Hongtao, Z. Hui, and W. Bingshun 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis Surg Oncol 21 2012 e165 e170
40. B.H. Byun, C.B. Kong, and J. Park Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities J Nucl Med 54 2013 1725 1732
41. R. Rakheja, W. Makis, and S. Skamene Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients AJR Am J Roentgenol 198 2012 1409 1416
42. M. Schulte, D. Brecht-Krauss, and B. Heymer Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET J Nucl Med 41 2000 1695 1701
43. ESMO/European Sarcoma Network Working Group Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 Suppl 3 2014 iii113 iii123
44. L.P. Adler, H.F. Blair, and R.P. Williams Grading liposarcomas with PET using [18F]FDG J Comput Assist Tomogr 14 1990 960 962
45. N. Nair, A. Ali, and A.A. Green Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans Clin Positron Imaging 3 2000 79 83
46. G.J. Cheon, M.S. Kim, and J.A. Lee Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI J Nucl Med 50 2009 1435 1440
47. J. Bajpai, R. Kumar, and V. Sreenivas Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis J Pediatr Hematol Oncol 33 2011 e271 e278
48. H.J. Im, T.S. Kim, and S.Y. Park Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma Eur J Nucl Med Mol Imaging 39 2012 39 49
49. K.J. Chang, C.B. Kong, and W.H. Cho Usefulness of increased F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement Skeletal Radiol 44 2014 529 537
50. D.S. Hawkins, J.G. Rajendran, and E.U. Conrad 3rd Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography Cancer 94 2002 3277 3284
51. Z. Ye, J. Zhu, and M. Tian Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET Ann Nucl Med 22 2008 475 480
52. K. Hamada, Y. Tomita, and A. Inoue Evaluation of chemotherapy response in osteosarcoma with FDG-PET Ann Nucl Med 23 2009 89 95
53. T. Denecke, P. Hundsdorfer, and D. Misch Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters Eur J Nucl Med Mol Imaging 37 2010 1842 1853
54. L.L. Gaston, C. Di Bella, and J. Slavin 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different Skeletal Radiol 40 2011 1007 1015
55. B.H. Byun, C.B. Kong, and I. Lim Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential (1)(8)F-FDG PET/CT and MRI Eur J Nucl Med Mol Imaging 41 2014 1553 1562
56. B.H. Byun, C.B. Kong, and I. Lim Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma Skeletal Radiol 42 2013 1673 1681
57. N. Quartuccio, J. Fox, and D. Kuk Pediatric bone sarcoma: diagnostic performance of (18)F-FDG PET/CT versus conventional imaging for initial staging and follow-up AJR Am J Roentgenol 204 2015 153 160
58. G. Treglia, M. Salsano, and A. Stefanelli Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis Skeletal Radiol 41 2012 249 256
59. R.C. Martin 2nd, and M.F. Brennan Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch Surg 138 2003 281 285
60. M. Bernstein, H. Kovar, and M. Paulussen Ewing's sarcoma family of tumors: current management Oncologist 11 2006 503 519
61. C. Franzius, J. Sciuk, and H.E. Daldrup-Link FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy Eur J Nucl Med 27 2000 1305 1311
62. T. Gyorke, T. Zajic, and A. Lange Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours Nucl Med Commun 27 2006 17 24
63. H.U. Gerth, K.U. Juergens, and U. Dirksen Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors J Nucl Med 48 2007 1932 1939
64. M. Kleis, H. Daldrup-Link, and K. Matthay Diagnostic value of PET/CT for the staging and restaging of pediatric tumors Eur J Nucl Med Mol Imaging 36 2009 23 36
65. M. Charest, M. Hickeson, and R. Lisbona FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases Eur J Nucl Med Mol Imaging 36 2009 1944 1951
66. R.J. Mody, C. Bui, and R.J. Hutchinson FDG PET imaging of childhood sarcomas Pediatr Blood Cancer 54 2010 222 227
67. P. Sharma, B.C. Khangembam, and K.C. Suman Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma Eur J Nucl Med Mol Imaging 40 2013 1036 1043
68. H.E. Daldrup-Link, C. Franzius, and T.M. Link Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET AJR Am J Roentgenol 177 2001 229 236
69. C. Franzius, H.E. Daldrup-Link, and J. Sciuk FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT Ann Oncol 12 2001 479 486
70. J. Aoki, H. Watanabe, and T. Shinozaki FDG-PET in differential diagnosis and grading of chondrosarcomas J Comput Assist Tomogr 23 1999 603 608
71. W. Brenner, E.U. Conrad, and J.F. Eary FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients Eur J Nucl Med Mol Imaging 31 2004 189 195
72. F. Feldman, R. Van Heertum, and C. Saxena 18FDG-PET applications for cartilage neoplasms Skeletal Radiol 34 2005 367 374
73. F. Feldman, R. Vanheertum, and C. Saxena 18Fluoro-deoxyglucose positron emission tomography evaluation of benign versus malignant osteochondromas: preliminary observations J Comput Assist Tomogr 30 2006 858 864
74. N.C. Purandare, V. Rangarajan, and M. Agarwal Integrated PET/CT in evaluating sarcomatous transformation in osteochondromas Clin Nucl Med 34 2009 350 354
75. S. Stacchiotti, G.P. Dagrada, and C. Morosi Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib Clin Sarcoma Res 2 2012 22
76. S. Stacchiotti, M.A. Pantaleo, and A. Astolfi Activity of sunitinib in extraskeletal myxoid chondrosarcoma Eur J Cancer 50 2014 1657 1664
77. T.J. Bradshaw, S. Yip, and N. Jallow Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy Int J Radiat Oncol Biol Phys 89 2014 399 405
78. T.K. Leung, C.H. Chen, and C.H. Lai Bone and joint protection ability of ceramic material with biological effects Chin J Physiol 55 2012 47 54
79. B.S. Purohit, P. Dulguerov, and K. Burkhardt Dedifferentiated laryngeal chondrosarcoma: combined morphologic and functional imaging with positron-emission tomography/magnetic resonance imaging Laryngoscope 124 2014 E274 E277
80. M.L. Klem, R.K. Grewal, and L.H. Wexler PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools J Pediatr Hematol Oncol 29 2007 9 14
81. T.W. McLean, and K.S. Buckley Pediatric genitourinary tumors Curr Opin Oncol 22 2010 268 273
82. D. Roberge, S. Vakilian, and Y.Z. Alabed FDG PET/CT in initial staging of adult soft-tissue sarcoma Sarcoma 2012 2012 960194
83. U. Tateishi, A. Hosono, and A. Makimoto Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma Ann Nucl Med 23 2009 155 161
84. K.C. Suman, P. Sharma, and H. Singh Primary rhabdomyosarcoma of pulmonary artery: 18F-FDG PET/CT for detecting recurrence in a rare tumor Clin Nucl Med 38 2013 e155 e156
85. D. Roberge, M. Hickeson, and M. Charest Initial McGill experience with fluorodeoxyglucose PET/CT staging of soft-tissue sarcoma Curr Oncol 17 2010 18 22
86. G. Norman, D. Fayter, and K. Lewis-Light An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review BMJ Open 5 2015 e006030
87. M. De Wit, A. Raabe, and B. Seegers Time benefit in the assessment of recurrences following fractionated radiotherapy in an experimental tumour system using positron-emission tomography with 18F-fluorodeoxyglucose Int J Radiat Biol 80 2004 529 539
88. A. Raabe, R. Buchert, and B. Seegers Potential time benefit in the assessment of recurrent rat rhabdomyosarcoma using positron emission tomography (PET) with (18)fluorodeoxyglucose depends on therapy-specific growth delay Strahlenther Onkol 182 2006 610 615
89. F. Peng, G. Rabkin, and O. Muzik Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study Clin Nucl Med 31 2006 394 397
90. M.W. Arush, O. Israel, and S. Postovsky Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma Pediatr Blood Cancer 49 2007 901 905
91. D. Rommel, J. Abarca-Quinones, and A. Bol Early monitoring of external radiation therapy by [18F]-fluoromethylcholine positron emission tomography and 3-T proton magnetic resonance spectroscopy: an experimental study in a rodent rhabdomyosarcoma model Nucl Med Biol 37 2010 645 653
92. K.V. Dharmarajan, L.H. Wexler, and S. Gavane Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma Int J Radiat Oncol Biol Phys 84 2012 996 1002
93. K.A. Kern, A. Brunetti, and J.A. Norton Metabolic imaging of human extremity musculoskeletal tumors by PET J Nucl Med 29 1988 181 186
94. O.E. Nieweg, J. Pruim, and H.J. Hoekstra Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma J Nucl Med 35 1994 90 92
95. S. Kosuda, R.L. Wahl, and H.B. Grossman Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET Ann Nucl Med 11 1997 263 266
96. A.C. Kole, O.E. Nieweg, and R.J. van Ginkel Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose Ann Surg Oncol 4 1997 57 63
97. H. Jadvar, and A.J. Fischman Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography Clin Positron Imaging 2 1999 153 158
98. C. Conill, X. Setoain, and L. Colomo Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma J Magn Reson Imaging 27 2008 625 628
99. H. Kudo, T. Inaoka, and W. Tokuyama Round cell liposarcoma arising in the left foot: MRI and PET findings Jpn J Radiol 30 2012 852 857
100. S. Ozguven, M. Aras, and S. Inanir Mesenteric metastases of purely myxoid liposarcoma: an unusual behavior of primary tumor depicted on fludeoxyglucose positron emission tomography/computerized tomography Indian J Nucl Med 30 2015 82 83
101. M.P. Reddy, G.P. Sangster, and A.M. Takalkar Accurate grading of 3 synchronous liposarcomas assessed by PET-CT in a single patient Clin Nucl Med 32 2007 937 939
102. S. Okazumi, A. Dimitrakopoulou-Strauss, and M.H. Schwarzbach Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis Hell J Nucl Med 12 2009 223 228
103. W. Brenner, J.F. Eary, and W. Hwang Risk assessment in liposarcoma patients based on FDG PET imaging Eur J Nucl Med Mol Imaging 33 2006 1290 1295
104. B.H. Choi, S.H. Yoon, and S. Lee Primary malignant fibrous histiocytoma in mediastinum: imaging with (18)F-FDG PET/CT Nucl Med Mol Imaging 46 2012 304 307
105. S.S. Hwang, S.Y. Park, and Y.H. Park The CT and F-FDG PET/CT appearance of primary renal malignant fibrous histiocytoma J Med Imaging Radiat Oncol 54 2010 365 367
106. W. Zheng, J. Chen, and J. Liu FDG PET/CT findings of malignant fibrous histiocytoma of the stomach Clin Nucl Med 2014 10.1097/rlu.0000000000000610 [Epub ahead of print]
107. A. Dong, J. Gong, and Y. Wang MRI and FDG PET/CT findings of malignant fibrous histiocytoma of the prostate Clin Nucl Med 39 2014 889 891
108. H.W. Noh, K.J. Park, and J.S. Sun Primary pulmonary malignant fibrous histiocytoma mimics pulmonary artery aneurysm with partial thrombosis: various radiologic evaluations Eur Radiol 18 2008 1653 1657
109. L. Ho, M. Meka, and B.K. Gamble Left maxillary sinus malignant fibrous histiocytoma on FDG PET-CT Clin Nucl Med 34 2009 967 968
110. E. Kobayashi, A. Kawai, and K. Seki Bilateral adrenal gland metastasis from malignant fibrous histiocytoma: value of [F-18]FDG PET-CT for diagnosis of occult metastases Ann Nucl Med 20 2006 695 698
111. G. Treglia, P. Mirk, and A. Stefanelli 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review Clin Imaging 36 2012 167 175
112. D.M. King The radiology of gastrointestinal stromal tumours (GIST) Cancer Imaging 5 2005 150 156
113. M. Yamada, Y. Niwa, and T. Matsuura Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy Scand J Gastroenterol 42 2007 633 641
114. I. Gayed, T. Vu, and R. Iyer The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 2004 17 21
115. T. Kaneta, S. Takahashi, and H. Fukuda Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study Ann Nucl Med 23 2009 459 464
116. Y. Otomi, H. Otsuka, and N. Morita Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors J Med Invest 57 2010 270 274
117. M.R. Koch, J.P. Jagannathan, and A.B. Shinagare Imaging features of primary anorectal gastrointestinal stromal tumors with clinical and pathologic correlation Cancer Imaging 12 2013 557 565
118. K. Yoshikawa, M. Shimada, and N. Kurita Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors Surg Today 43 2013 1162 1167
119. A.J. Winant, M.J. Gollub, and J. Shia Imaging and clinicopathologic features of esophageal gastrointestinal stromal tumors AJR Am J Roentgenol 203 2014 306 314
120. L. Evangelista, A.R. Cervino, and M. Gregianin FDG-PET/CT visualises a case of primary hyperparathyroidism in patient with GIST Minerva Endocrinol 35 2010 193 195
121. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
122. D. Fuster, J.R. Ayuso, and A. Poveda Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study Q J Nucl Med Mol Imaging 55 2011 680 687
123. A.T. van Oosterom, I. Judson, and J. Verweij Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 2001 1421 1423
124. G. Antoch, J. Kanja, and S. Bauer Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45 2004 357 365
125. H. Choi, C. Charnsangavej, and S. de Castro Faria CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 2004 1619 1628
126. P.L. Jager, J.A. Gietema, and W.T. van der Graaf Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET Nucl Med Commun 25 2004 433 438
127. G.W. Goerres, R. Stupp, and G. Barghouth The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 2005 153 162
128. D. Goldstein, B.S. Tan, and M. Rossleigh Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response-an AGITG study Oncology 69 2005 326 332
129. C.H. Holdsworth, R.D. Badawi, and J.B. Manola CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor AJR Am J Roentgenol 189 2007 W324 W330
130. G.D. Demetri, M.C. Heinrich, and J.A. Fletcher Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure Clin Cancer Res 15 2009 5902 5909
131. J.O. Prior, M. Montemurro, and M.V. Orcurto Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor J Clin Oncol 27 2009 439 445
132. J. Maurel, A.S. Martins, and A. Poveda Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish group for research on sarcomas Cancer 116 2010 3692 3701
133. S. Stroobants, J. Goeminne, and M. Seegers 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2003 2012 2020
134. A. Gelibter, M. Milella, and A. Ceribelli PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients Anticancer Res 24 2004 3147 3151
135. J.J. Zaknun, D. Kendler, and R. Moncayo F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib Clin Nucl Med 30 2005 749 751
136. S. Bauer, R.A. Hilger, and T. Muhlenberg Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors Br J Cancer 110 2014 1155 1162
137. I. Judson, M. Scurr, and K. Gardner Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma Clin Cancer Res 20 2014 3603 3612
138. A.J. Wagner, R. Chugh, and L.S. Rosen A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas Clin Cancer Res 19 2013 6020 6029
139. U. Ronellenfitsch, B. Wangler, and S. Niedermoser Importance of PET for surgery of gastrointestinal stromal tumors Chirurg 85 2014 493 499 [in German]
140. E. Valls-Ferrusola, J.R. Garcia-Garzon, and A. Ponce-Lopez Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec(R)) by 18F-FDG PET/CT Rev Esp Enferm Dig 104 2012 360 366
141. N. Tokumoto, K. Tanabe, and T. Misumi The usefulness of preoperative 18FDG positron-emission tomography and computed tomography for predicting the malignant potential of gastrointestinal stromal tumors Dig Surg 31 2014 79 86
142. A. Williams, A. Gutzeit, and M. Germer PET-negative gastrointestinal stromal tumors Case Rep Oncol 6 2013 508 513
143. C. Dietrich, E. Hartung, and A. Ignee The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET Ultraschall Med 29 2008 276 277
144. F. Bertagna, G. Bosio, and E. Orlando Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST) Nucl Med Rev Cent East Eur 13 2010 76 80
145. S. Hahn, S. Bauer, and T.A. Heusner Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection? Eur J Radiol 80 2011 670 674